Sinopharm Group Co (HK:1099) has released an update.
Sinopharm Group Co. Ltd has released its principal unaudited financial data for the first half of 2024, revealing a modest increase in total assets by 3.39%, revenue by 2.55%, and net profit attributable to shareholders by 1.62% compared to the previous year. Despite the growth, the company experienced a decrease in net cash flow from operating activities and a slight dip in the weighted average return on net assets. The financial indicators suggest steady performance amidst challenging market conditions.
For further insights into HK:1099 stock, check out TipRanks’ Stock Analysis page.
